会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 证券代码：600739 证券简称：辽宁成大 公告编号：临 2023-061 会议召开方式：上证路演中心网络文字互动 辽宁成大股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 10 月 13 日（星期五）16:00-17:00 （一）会议召开时间：2023 年 10 月 13 日（星期五）16:00-17:00 （二）会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 09 月 28 日（星期四）至 10 月 12 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 liutong@chengda.com.cn 进行提问 ...

证券代码：600739 证券简称：辽宁成大 公告编号：临 2023-059 辽宁成大股份有限公司 关于 2022 年度第二期债权融资计划到期兑付公告 2022 年 5 月 31 日，辽宁成大股份有限公司（以下简称"公司"）2021 年年 度股东大会审议通过了《关于申请融资额度的议案》，公司及控股子公司拟向包 含但不限于银行、信托公司、证券公司、融资租赁公司等机构申请融资额度，及 申请北京金融资产交易所债权融资计划，总金额不超过人民币 180 亿元。公司于 2022 年 9 月 6 日完成了 2022 年度第二期债权融资计划的发行，金额为人民币 3 亿元，票面利率为 3.90%。 2022 年度第二期债权融资计划已于 2023 年 9 月 7 日到期，公司已完成该期 债权融资计划本息的兑付。 特此公告。 辽宁成大股份有限公司董事会 2023 年 9 月 8 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥4.68 billion, a decrease of 40.17% compared to ¥7.82 billion in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥496.59 million, down 47.08% from ¥938.38 million year-on-year[19]. - The basic earnings per share for the first half of 2023 was ¥0.3258, a decline of 46.89% from ¥0.6134 in the previous year[20]. - The company achieved a revenue of 4.68 billion yuan in the reporting period, a year-on-year decrease of 40.17%[37]. - The net profit attributable to shareholders was 497 million yuan, down 47.08% year-on-year[37]. - The biopharmaceutical segment's revenue was 872 million yuan, a decline of 1.15% year-on-year, primarily due to intensified market competition[38]. - The supply chain services segment reported a revenue of 3.49 billion yuan, down 44.94% year-on-year, mainly due to significant declines in steel and coal business revenues[39]. - The energy development segment's revenue was 318 million yuan, a decrease of 47.46% year-on-year, with a net loss of 558 million yuan, worsening year-on-year[41]. - The company's net profit for the first half of 2023 was approximately ¥479.34 million, a decrease of 48.64% compared to ¥933.29 million in the same period last year[117]. - The EBITDA interest coverage ratio dropped to 3.01 from 6.03, a decline of 50.08%, primarily due to a decrease in the scale of medical supplies exports and increased losses in energy development[118]. Cash Flow and Financial Position - The net cash flow from operating activities improved to approximately ¥36.54 million, compared to a negative cash flow of ¥11.92 million in the same period last year[19]. - The company maintained a loan repayment rate of 100% during the reporting period[118]. - The interest payment ratio remained stable at 100%[118]. - The company's cash flow from investment activities showed a significant negative change of -199.65%, amounting to -¥1,613,423,351.50, due to unreturned entrusted financial management funds[44]. - The company reported a significant increase in other receivables, which rose to CNY 7.92 billion from CNY 7.00 billion, an increase of approximately 12.9%[125]. - The company's cash and cash equivalents decreased significantly from CNY 8.66 billion to CNY 6.22 billion, a reduction of about 28.2%[121]. - The company experienced a net decrease in cash and cash equivalents of 2,466,736,780.17 RMB in the first half of 2023, compared to a decrease of 90,982,726.19 RMB in the same period of 2022[138]. Assets and Liabilities - The company's total assets at the end of the reporting period were approximately ¥48.22 billion, a slight increase of 0.15% from ¥48.15 billion at the end of the previous year[19]. - The total liabilities decreased by 38.59% year-on-year to ¥2,140,067,918.75, primarily due to the reclassification of short-term payable bonds[45]. - The company's total current assets decreased to CNY 12.68 billion from CNY 13.40 billion, representing a decline of approximately 5.4%[122]. - The total liabilities increased to CNY 16.02 billion from CNY 15.92 billion, indicating a rise of about 0.6%[123]. - The total owner's equity slightly decreased to CNY 32.20 billion from CNY 32.23 billion, a decline of about 0.1%[123]. Sector Performance - The decline in operating revenue was primarily due to a decrease in the scale of bulk commodity trading and medical supplies exports[21]. - The company operates in four main sectors: pharmaceutical and medical, financial investment, supply chain services, and energy development[26]. - The financial investment segment saw a year-on-year increase in performance due to a recovering securities market and improved insurance business, with strategic investments in Guangfa Securities and China Insurance[29]. - The supply chain services faced challenges with a decline in textile and apparel exports, totaling $142.7 billion, down 8.8% year-on-year[30]. - The energy development segment reported fluctuations in international crude oil prices, with NYMEX crude oil prices ranging from $63.64 to $83.53 per barrel during the first half of the year[30]. Research and Development - In the pharmaceutical sector, the company focuses on vaccine development, particularly multi-valent vaccines and new gene-engineered vaccines, with significant growth opportunities in the domestic vaccine market[26]. - The company has developed multiple vaccine technology platforms, including bacterial, viral, and recombinant protein vaccine platforms, enhancing its R&D capabilities[35]. - The company is actively exploring the construction of an mRNA vaccine technology platform to strengthen its core R&D capabilities[35]. - The company plans to increase sales of the inactivated Japanese encephalitis vaccine and enhance R&D investment to mitigate risks associated with a single product structure[66]. Risk Management - The company has indicated potential risks related to its operational and development strategies in the forward-looking statements section of the report[6]. - The company faces risks from industry policy changes and competition, which could impact its operations significantly[62]. - The supply chain service industry is highly competitive, with a slowdown in demand for bulk production materials, which may pose operational risks for the company[67]. - The company has implemented a strict customer and supplier admission system to assess credit risks and ensure logistics safety[67]. Environmental and Social Responsibility - Chengda Biopharmaceutical is classified as a key pollutant discharge unit and is committed to complying with environmental regulations and standards[75]. - Chengda Bio has installed a sewage online monitoring system to monitor COD, ammonia nitrogen, pH value, and flow in real-time, ensuring all pollutants meet discharge standards[82]. - Xinjiang Baoming has implemented a comprehensive wastewater treatment system, allowing for the recycling of treated wastewater as production supplementary water, thus reducing fresh water intake[77]. - Chengda Bio promotes energy conservation and carbon reduction awareness among employees, implementing measures to reduce carbon emissions during production[85]. Corporate Governance - The company has committed to respecting the actual control of the Liaoning Provincial State-owned Assets Supervision and Administration Commission for 24 months following the listing of Chengda Biology, ensuring no attempts to gain control over Liaoning Chengda[88]. - The company has confirmed that it will limit the voting rights of shares held by Shaoguan Gaoteng to 10% of the total share capital, which corresponds to 152,970,981 shares, for a period of 24 months post-listing[88]. - There are no significant lawsuits or arbitration matters reported during the reporting period[93]. - The company and its controlling shareholders have not failed to fulfill any court judgments or large debt obligations during the reporting period[94].

辽宁恒信律师事务所 法律意见书 辽宁恒信律师事务所 关于辽宁成大股份有限公司2023年第二次临时股东大会的 法律意见书 致：辽宁成大股份有限公司 辽宁恒信律师事务所（以下简称"本所"）接受辽宁成大股份有限公司（以 下简称"公司"）的委托，指派翟春雪律师、周玉律师（以下简称"本所律师"） 出席公司2023年第二次临时股东大会（以下简称"本次股东大会"），并对本次 股东大会的合法性进行见证。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以 下简称"《股东大会规则》"）等有关法律、法规和规范性文件以及《辽宁成大 股份有限公司章程》（以下简称"《公司章程》"），本所律师审查了公司提供 的如下文件： 1. 公司现行的《公司章程》； 2. 公司于2023年7月31日召开的第十届董事会第十九次（临时）会议的《董 事会决议》； 3. 公司于2023年8月1日刊登于《中国证券报》《上海证券报》《证券时报》 《证券日报》与上海证券交易所网站（http://www.sse.com.cn）的《辽宁成大股份 有限公司第十届董事会第十九次（临时） ...

证券代码：600739 证券简称：辽宁成大 公告编号：2023-058 辽宁成大股份有限公司 2023 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会提议召开，由董事长尚书志先生主持，以记名投票方式表 决。会议采用现场投票和网络投票相结合的方式进行。会议的召开、表决方式符 合《公司法》及《公司章程》的规定。 (一) 股东大会召开的时间：2023 年 8 月 16 日 (二) 股东大会召开的地点：公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (五) 公司董事、监事和董事会秘书的出席情况 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 111 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 574,574,070 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 ...

辽宁恒信律师事务所 关于 辽宁成大股份有限公司差异化分红 之 法律意见书 辽宁恒信律师事务所 HENG XIN LAW OFFICE 辽宁省大连市中山区人民路68号宏誉大厦27楼 邮政编码:116001 27/F., Gold Name Commercial Tower, 68 Renmin Road, Dalian, China, 1160 电话:(86-411) 82825959 传真:(86-411) 82825518 邮箱1: mail@hxlawyer.com 订宁恒信律师事务所 关于辽宁成大股份有限公司 差异化分红之法律意见书 恒信(2022) -证DLF220318号 致:辽宁成大股份有限公司 辽宁恒信律师事务所(以下简称"本所")接受辽宁成大股份有限公司(以 下简称"辽宁成大"或"公司"）委托,就辽宁成大 2022年度利润分配所涉及 的差异化分红(以下简称"本次差异化分红")相关事项,依据《中华人民共和 国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简 称"《证券法》")、《上海证券交易所股票上市规则》《上市公司股份回购规 则》《关于支持上市公司回购股份的意见》《上海证券 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2023-057 辽宁成大股份有限公司 2022 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.15022 元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/8/17 | － | 2023/8/18 | 2023/8/18 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经本公司 2023 年 6 月 21 日的 2022 年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份 ...

证券代码：600739 证券简称：辽宁成大 公告编号：临 2023-056 辽宁成大股份有限公司 关于股东股份质押延期购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至本公告披露日，辽宁成大股份有限公司（以下简称"公司"）股东韶 关市高腾企业管理有限公司（以下简称"韶关高腾"）持有公司 234,004,700 股， 占公司总股本比例为 15.30%。本次质押延期购回后，韶关高腾累计质押股份数 量为 137,881,149 股，占其所持股份比例为 58.92%，占公司总股本比例为 9.01%。 公司于 2023 年 8 月 9 日接到股东韶关高腾函告，获悉韶关高腾对其质押的 公司部分股份办理了质押延期购回，具体事宜如下。 | | | | 是否为 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 是否 | | 限售股 | | | | 延期 | | | 占公 | ...

证券代码：600739 证券简称：辽宁成大 公告编号：临 2023-037 辽宁成大股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 6 月 2 日（星期五）15:00-16:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 5 月 26 日（星期五）至 6 月 1 日（星期四）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 liutong@chengda.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 辽宁成大股份有限公司（以下简称"公司"）已于 2023 年 4 月 15 日发布公 司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成 果、财务状况，公司计划于 2023 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,067,470,409.28, a decrease of 41.91% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥303,528,102.98, representing an increase of 9.90% year-on-year[5]. - The net profit from continuing operations for Q1 2023 was ¥305,943,174.87, a decrease of 39.1% compared to ¥502,052,832.42 in Q1 2022[30]. - The total comprehensive income for Q1 2023 was ¥329,340,903.33, compared to ¥436,639,102.20 in Q1 2022, indicating a decrease of 24.6%[30]. - The total operating revenue for Q1 2023 was ¥2,126,287,199.60, down from ¥3,083,447,353.75 in Q1 2022, reflecting a decline of 30.9%[29]. - The investment income for Q1 2023 increased significantly to ¥436,469,217.04, compared to ¥193,745,727.21 in Q1 2022, representing a growth of 125.5%[29]. - The total sales revenue from goods and services received in Q1 2023 was ¥2,410,052,670.78, down from ¥3,845,759,149.89 in Q1 2022, a decrease of 37.3%[36]. - The total operating costs for Q1 2023 were ¥2,126,287,199.60, down from ¥3,083,447,353.75 in Q1 2022, a decrease of 30.9%[29]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥385,585,423.69, a decline of 261.76% compared to the previous year[5]. - The cash flow from operating activities for Q1 2023 was negative at -¥385,585,423.69, compared to a positive cash flow of ¥238,371,121.05 in Q1 2022[36]. - Cash and cash equivalents as of March 31, 2023, were RMB 5,916,332,513.09, down from RMB 8,661,343,948.37 at the end of 2022, representing a decline of approximately 32%[20]. - The net cash inflow from investment activities for Q1 2023 was ¥331,977,098.02, a decrease from ¥909,534,584.76 in Q1 2022, reflecting a decline of 63.5%[36]. - The net cash flow from investing activities was -1,365,073,812.52 CNY, compared to -563,506,986.98 CNY in the previous year[38]. - The net cash flow from financing activities was -984,088,722.47 CNY, compared to -738,985,901.60 CNY in the previous year[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥47,483,377,333.89, a decrease of 1.38% from the end of the previous year[7]. - Total liabilities decreased to RMB 14,925,379,248.62 from RMB 15,920,151,988.78, indicating a reduction of about 6%[25]. - Total current assets amounted to ¥13,404,445,003.22 as of December 31, 2022[57]. - Total non-current assets reached ¥34,744,001,483.82, with a slight increase of ¥4,512,327.44 from the previous period[60]. - Total liabilities amounted to ¥15,920,151,988.78, showing a slight increase of ¥4,116,069.54[63]. - Total equity attributable to shareholders was ¥28,708,560,566.74, with a minor adjustment of ¥204,294.96[63]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 71,954[12]. - The top ten shareholders included Shaoguan Gaoteng Enterprise Management Co., Ltd. with a 15.30% stake and Liaoning State-owned Assets Management Co., Ltd. with an 11.11% stake[12]. Research and Development - The research and development expenses for Q1 2023 were ¥44,378,770.68, slightly down from ¥47,298,376.40 in Q1 2022, a decrease of 6.1%[29].